Evidence map›Paper›PMID 38826238›Full record

ArticlebioRxiv : the preprint server for biology2024

ZBTB11 Depletion Targets Metabolic Vulnerabilities in K-Ras Inhibitor Resistant PDAC.

Nathan L Tran, Jiewei Jiang, Min Ma, Gillian E Gadbois, Kevin C M Gulay, Alyssa Verano, Haowen Zhou, Chun-Teng Huang, David A Scott, Anne G Bang and 4 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Nathan L TranDepartment of Chemistry and Biochemistry, University of California San Diego, La Jolla, CA.
Jiewei JiangDepartment of Chemistry and Biochemistry, University of California San Diego, La Jolla, CA.
Min MaDepartment of Chemistry and Biochemistry, University of California San Diego, La Jolla, CA.
Gillian E GadboisDepartment of Chemistry and Biochemistry, University of California San Diego, La Jolla, CA.
Kevin C M GulayDepartment of Surgery, Division of Surgical Oncology, UCSD Moores Cancer Center, University of California San Diego, La Jolla, CA.
Alyssa VeranoDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02115.
Haowen ZhouSanford Burnham Prebys Medical Discovery Institute, La Jolla, CA.
Chun-Teng HuangSanford Burnham Prebys Medical Discovery Institute, La Jolla, CA.
David A ScottSanford Burnham Prebys Medical Discovery Institute, La Jolla, CA.
Anne G BangSanford Burnham Prebys Medical Discovery Institute, La Jolla, CA.
Herve TiriacDepartment of Surgery, Division of Surgical Oncology, UCSD Moores Cancer Center, University of California San Diego, La Jolla, CA.
Andrew M LowyDepartment of Surgery, Division of Surgical Oncology, UCSD Moores Cancer Center, University of California San Diego, La Jolla, CA.
Eric S WangCancer Molecular Therapeutics Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA.
Fleur M FergusonDepartment of Chemistry and Biochemistry, University of California San Diego, La Jolla, CA.ORCID 0000-0003-4091-7617

Funding

Structural BiologyP30CA030199 · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · 1985 to 2025
$23.0M
Contemporary Approaches to Cancer Cell Signaling and CommunicationT32CA009523 · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 1985 to 2025
$3.0M
Molecular Biophysics Training Grant at UC San DiegoT32GM139795 · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 2025 to 2025
$545k
NCI NIH HHS P30 CA030199NCI NIH HHS T32 CA009523NIGMS NIH HHS T32 GM139795NIH HHS S10 OD036254
6 · The paper itself

Abstract

Over 95% of pancreatic ductal adenocarcinomas (PDAC) harbor oncogenic mutations in K-Ras. Upon treatment with K-Ras inhibitors, PDAC cancer cells undergo metabolic reprogramming towards an oxidative phosphorylation-dependent, drug-resistant state. However, direct inhibition of complex I is poorly tolerated in patients due to on-target induction of peripheral neuropathy. In this work, we develop molecular glue degraders against ZBTB11, a C

Identifiers

PMID38826238
PMCPMC11142081

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.